Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 1,523 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,523 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $91.38, for a total transaction of $139,171.74. Following the sale, the chief financial officer now owns 73,039 shares in the company, valued at $6,674,303.82. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The shares were sold at an average price of $92.62, for a total transaction of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The shares were sold at an average price of $90.42, for a total transaction of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The shares were sold at an average price of $88.36, for a total transaction of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The shares were sold at an average price of $70.03, for a total transaction of $2,383,050.87.
• On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The shares were sold at an average price of $67.73, for a total transaction of $1,509,092.13.
• On Monday, January 29th, Michael Burkes Brophy sold 3,235 shares of Natera stock. The shares were sold at an average price of $65.09, for a total transaction of $210,566.15.

Natera Trading Up 2.7 %

Shares of NTRA stock traded up $2.43 during trading hours on Tuesday, reaching $91.04. 1,178,233 shares of the stock were exchanged, compared to its average volume of 1,470,075. Natera, Inc. has a 12-month low of $36.90 and a 12-month high of $98.82. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. The company’s 50-day moving average price is $86.40 and its 200-day moving average price is $66.49. The firm has a market capitalization of $10.99 billion, a price-to-earnings ratio of -24.02 and a beta of 1.37.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The firm had revenue of $311.11 million during the quarter, compared to analysts’ expectations of $300.38 million. As a group, equities analysts anticipate that Natera, Inc. will post -2.35 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on NTRA shares. Craig Hallum started coverage on shares of Natera in a report on Monday, April 8th. They issued a “buy” rating and a $117.00 price target on the stock. Stephens reiterated an “overweight” rating and issued a $78.00 price target on shares of Natera in a report on Tuesday, January 30th. StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a report on Tuesday. Piper Sandler lifted their price target on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Finally, BTIG Research boosted their target price on shares of Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a report on Friday, December 29th. One equities research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Natera has an average rating of “Moderate Buy” and an average price target of $86.40.

Hedge Funds Weigh In On Natera

A number of large investors have recently made changes to their positions in NTRA. RiverPark Advisors LLC purchased a new stake in Natera in the 4th quarter valued at about $27,000. Principal Securities Inc. purchased a new stake in Natera in the 4th quarter valued at about $32,000. Arcadia Investment Management Corp MI boosted its position in Natera by 47.8% in the 1st quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock valued at $49,000 after buying an additional 174 shares during the period. Oliver Lagore Vanvalin Investment Group boosted its position in Natera by 109.3% in the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after buying an additional 389 shares during the period. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Natera in the 3rd quarter valued at about $44,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.